This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

David Sobek

Contributor

Sobek writes on biotech, with a focus on small-cap oncology and antibiotics companies. He received a PhD in political science from Penn State in 2003. He is the proprietor of Sobek Analytics.


David Sobek
By This Author:
« Back
Page 1 of 6

2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses

By David Sobek

Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.

09:35AM 12/18/14

Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests

By David Sobek

Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.

11:17AM 11/19/14

Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline

By David Sobek

The diversification away from Xtandi has only just begun.

08:00AM 11/05/14

Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths

By David Sobek

Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.

09:35AM 10/15/14

Acceleron Hit Over Competitive Concerns, but Investors Overlook Rest of Pipeline

By David Sobek

An Acceleron update in December could reignite investor interest in the stock.

09:21AM 10/02/14

Safety Worries Over Celgene's Experimental Crohn's Drug Overblown

By David Sobek

The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.

08:26AM 09/17/14

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

By David Sobek

The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)

09:36AM 09/10/14

Tetraphase Oral Antibiotic Data Look Good

By David Sobek

Tetraphase is on track to begin second portion of pivotal study in the fourth quarter.

06:30AM 09/03/14

Previewing Tetraphase Oral Antibiotic Study Results

By David Sobek

Tetraphase will report data from a phase III study of eravacycline in which the experimental antibiotic is first given by intravenous infusion and then transitioned to an oral form.

08:00AM 08/27/14

Epizyme First Look at Blood Cancer Drug Encourages

By David Sobek

Epizyme's technology platform focuses on developing drugs to regulate a class of cancer-causing enzymes.

08:59AM 08/21/14

« Back
Page 1 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs